Previous 10 | Next 10 |
The Contingent Value Right (CVR) (NYSE: BMY.RT ) associated with Bristol Myers Squibb's ( BMY -2.2% ) $74B takeover of Celgene is down ~24% today in apparent reaction to management comments at a Citigroup conference revealing that the manufacturing plant for CAR T therapi...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, at 4:00 pm ET Morgan Stanley 18th Annual Global Healthcare C...
Bluebird bio ( BLUE +2.0% ) announces long-term results from a Phase 2/3 clinical trial, STARBEAM , evaluating gene therapy elivaldogene autotemcel (eli-cel, Lenti-D) in patients with cerebral adrenoleukodystrophy (CALD), a rare inherited metabolic disorder in which very long chain fa...
Long-term results from Phase 2/3 Starbeam study (ALD-102/LTF-304) suggest durability of response post eli-cel with all 20 patients who were free of major functional disabilities (MFDs) at two years (out of 23 evaluable patients) remaining MFD-free through last available follow-up, including...
FinancialBuzz.com News Commentary New York, NY (8/25/2020) – Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In particular, the top three diagnosed cancers accounted for over a third of total global cases. ...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including data from the Phase 2/3 Starbeam study...
Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...
RL, TPR, BLUE, and NOG were recently downgraded to Strong Sell ratings. It's not a good sign when stocks are struggling in a bear market and can indicate serious problems in their businesses. Find out what's behind these downgrades. The shortest bear market in history ended in the third wee...
bluebird bio (NASDAQ: BLUE ) : Q2 GAAP EPS of -$0.36 beats by $2.16 . Revenue of $198.89M (+1395.4% Y/Y) beats by $117.82M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
– First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206 – – Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketin...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...